Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Dapagliflozin vs Empagliflozin: they're closely matched on evidence (4.4 vs 4.5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Dapagliflozin and Empagliflozin are closely matched across evidence, studies, and safety.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (3)
Outcomes where both Dapagliflozin and Empagliflozin have evidence — compare verdict strength side-by-side.
Off-label use mirrors approved dosing (10 mg once daily) under a clinician. A prescription drug; not an approved longevity regimen.
Morning
Oral tablet (dapagliflozin)
Off-label use mirrors approved dosing (10–25 mg once daily in the morning) under a clinician. A prescription drug; not an approved longevity regimen.
Morning
Oral tablet (empagliflozin)
Weeks
Months to years
Months to years
Weeks to months
Weeks
Months to years
Months to years
Weeks to months
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
The New England journal of medicine (2019) · Rct · n=4744
DAPA-HF randomized trial in heart failure with reduced ejection fraction
Dapagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2020) · Rct · n=4304
DAPA-CKD randomized trial in a broad, largely non-diabetic chronic-kidney-disease population
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
The New England journal of medicine (2022) · Rct · n=6263
DELIVER randomized trial extending dapagliflozin to mildly reduced and preserved ejection fraction
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial in high-CV-risk type-2 diabetics
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation (2018) · Rct
Randomized evidence of empagliflozin benefit in established cardiovascular disease
Empagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2023) · Rct
EMPA-KIDNEY randomized trial in a broad chronic-kidney-disease population
Both Dapagliflozin and Empagliflozin are closely matched — the best choice depends on your specific health goals.
Both Dapagliflozin and Empagliflozin score equally (72) for support heart health.
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.